| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Immunology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Immunology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Immunology |
Recent Updates
Recently added Catalysts
Coya Therapeutics, Inc.$5.26
0 (0%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
112.83 M
EPS
-1.08
P/E Ratio
-
Value Trade
538.02 K
SEC Financials
Q1 2026Dilution Risk
Revenue
251.15 K
R&D Expenses
4.10 M
Operating CF
-6.21 M
Total Assets
53.27 M
Total Liabilities
4.30 M
Equity
48.97 M
D/E Ratio
12,345
-9.93 %
Week
5.48 %
1 Month
0.21 %
3 Month
-19.83 %
6 Month
1.26 %
5 Year
1.26 %
All Time
Cash Data
Cash Position
50.72 M
Monthly Burn
2.07 M
Runway
22.8 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
392.17 K
52 Week Range
3.71 - 7.75
% held by Insiders
14.69 %
% held by Institutions
34.74 %
Enterprise Value
62.10 M
Total Shares
23.44 M
Short %
4.98 %
Float Shares
18.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Coya Therapeutics, Inc.
210Total events
3Upcoming
42Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 207
Q3 2026
◆Additional DataClinical Data
Report additional single cell proteomics data from completed ALS and AD Investigator Initiated trials
ALSsource ↗
Q3 2026
Jun 18, 2026
Jun 15, 2026
◆Oral PresentationPresentation
Virtual webinar on intersection of repetitive head trauma, brain inflammation and neurodegenerative disease
repetitive head trauma, brain inflammation, neurodegenerative diseasesource ↗
Jun 8, 2026
▲OLE InitiatedTrial
First cohort of patients in ALSTARS trial began blinded active-treatment extension phase
ALSsource ↗
May 27, 2026
◆Oral PresentationPresentation
Presentation of ALSTARS trial design at 5th ALS Drug Development Summit
ALSsource ↗
May 12, 2026
▲Fast Track DesignationDesignation
FDA Fast Track Designation for COYA 302 in ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
Apr 10, 2026
▲PublicationPresentation
Publication of biomarker study in Annals of Clinical and Translational Neurology
ALSsource ↗
Apr 9, 2026
▲PublicationPresentation
Publication of biomarker study in Annals of Clinical and Translational Neurology
ALSsource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 38%
Micro Cap (rank 566 of 911)
Percentile RankCoya Therapeutics, Inc. faces pipeline headwinds (31/100), with $22M risk-adjusted pipeline value, led by COYA 302 in Amyotrophic Lateral Sclerosis (ALS) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COYA 302 Small molecule | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | NCT07161999 | 11% | $22M | RECRUITING | 120 | FAST | B (72) | Jul 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COYA 302 Fast Track | ALS | — | 2026-04-10 | p< 0.001 for 4-HNE and LBP; p= 0.001 for NfL; p< 0.001 for the rate of disease progression as measured by ALSFRS-R; ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment with LD IL-2 and CTLA-4 Ig were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9) Read More | Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS Read More | |
COYA 302 Fast Track | ALS | — | 2026-04-10 | p< 0.001 for 4-HNE and LBP; p= 0.001 for NfL; p< 0.001 for the rate of disease progression as measured by ALSFRS-R; ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment with LD IL-2 and CTLA-4 Ig were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9) Read More | Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS Read More | |
COYA 302 Fast Track | ALS | — | 2026-04-10 | p< 0.001 for 4-HNE and LBP; p= 0.001 for NfL; p< 0.001 for the rate of disease progression as measured by ALSFRS-R; ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment with LD IL-2 and CTLA-4 Ig were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9) Read More | Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COYA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COYA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COYACoya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics is set to present the design of its ALSTARS trial at the upcoming ENCALS 2026 Meeting. This presentation aims to share insights into the trial's structure and objectives, contributing to the ongoing discussions in the field of ALS research.
Read more →COYACoya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Coya Therapeutics is set to host a virtual webinar focusing on the relationship between repetitive head trauma, brain inflammation, and neurodegenerative diseases. This event aims to provide insights into how these factors interconnect and their implications for treatment. Further details about the webinar were not provided in the article.
Read more →COYACoya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Coya Therapeutics has announced that the first cohort of patients in the ALSTARS trial has commenced the blinded active-treatment extension phase. This marks a significant step in the trial process, although specific details about patient outcomes or trial objectives were not disclosed. The announcement indicates progress in the clinical trial's timeline.
Read more →COYACoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics is set to present the design of its ALSTARS trial at the upcoming 5th ALS Drug Development Summit. This presentation is expected to highlight the company's innovative approach to ALS treatment. Further details on the trial's objectives and methodologies will be discussed during the event.
Read more →COYACoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics has released its financial results for the first quarter of 2026 along with a corporate update. The article does not provide specific details regarding the financial performance or any significant developments within the company. Further insights into their strategies and future plans were also not disclosed.
Read more →COYACoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics has been granted Fast Track Designation by the U.S. FDA for its investigational treatment COYA 302, aimed at addressing Amyotrophic Lateral Sclerosis (ALS). This designation is intended to facilitate the development and review process for drugs that treat serious conditions and fill unmet medical needs. The move is expected to accelerate the availability of COYA 302 to patients.
Read more →COYA▼ -7.9%on this news
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics has published a study demonstrating a correlation between serum biomarkers and clinical outcomes in ALS patients. The research, involving 100 ALS patients and 100 healthy controls, found that specific biomarkers were significantly linked to survival and disease progression. These findings support the ongoing ALSTARS trial of COYA 302, which aims to enhance Treg function in ALS treatment.
Read more →COYACoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics has announced a planned transition in its board of directors, appointing Mark H. Pavao as an independent director. This change is part of the company's strategy to enhance its governance and oversight. Further details regarding the transition were not provided in the announcement.
Read more →COYACoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Coya Therapeutics has provided a corporate update and reported its financial results for FY 2025, highlighting significant advancements in its clinical trials, particularly the launch of the ALSTARS Phase 2 trial for ALS. The company received FDA acceptance for its IND application for COYA 302 targeting frontotemporal dementia and reported promising interim findings for COYA 303. Financially, Coya secured $23 million in a public offering, extending its cash runway into the second half of 2027, despite an increased net loss.
Read more →COYACoya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Coya Therapeutics will host a webinar on February 17, 2026, focusing on ALS drug development and patient care. The event will cover recent advancements and ongoing challenges in ALS treatment, highlighting Coya's COYA 302 therapy and its ALSTARS Phase 2 clinical trial. The webinar aims to engage participants in discussions about the evolving landscape of ALS therapies.
Read more →COYACoya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics announced a private placement of 2,522,727 shares at $4.40 each, raising approximately $11.1 million. The funds will be used to enhance manufacturing activities for COYA 302, an investigational therapy for neurodegenerative diseases. The offering is expected to close by January 30, 2026, pending customary conditions.
Read more →COYACoya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics' CEO Dr. Arun Swaminathan issued a letter to stockholders highlighting the company's strong position in advancing therapies for neurodegenerative diseases like ALS and FTD. With recent IND approvals and promising early clinical results, Coya is focused on key milestones in 2026. The company maintains a solid financial footing with significant cash reserves, allowing for continued operational momentum.
Read more →COYA▼ -5.1%on this news
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Coya Therapeutics announced that the FDA has accepted its IND application for COYA 302, aimed at treating frontotemporal dementia (FTD). This condition currently has no approved treatments, highlighting a significant unmet medical need. The investigational therapy is designed to enhance regulatory T cell function and may provide a new approach to managing FTD. Clinical trials are expected to follow, with topline results from an ongoing study anticipated soon.
Read more →COYACoya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics has received acceptance from Health Canada for its Clinical Trial Application (CTA) for COYA 302, allowing the initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. This Phase 2, placebo-controlled study aims to evaluate the efficacy and safety of COYA 302 in treating amyotrophic lateral sclerosis (ALS). The trial is already underway in the United States and will now expand to Canada, enhancing recruitment efforts.
Read more →COYACoya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update HOUSTON, TX
Coya Therapeutics reported its financial results for Q3 2025, highlighting significant advancements in its clinical pipeline, including FDA acceptance of the IND application for COYA 302 aimed at treating ALS. The company launched the ALSTARS Phase 2 trial and reported promising preclinical data for COYA 303. Financially, Coya secured $4.2 million from Dr. Reddy's Laboratories and completed a successful public offering, extending cash reserves. Despite these gains, the company recorded a net loss of $2.1 million, indicating a continued need for funding.
Read more →COYA▼ -5.2%on this news
Coya Therapeutics Announces Proposed Public Offering of Common Stock HOUSTON, TX
Coya Therapeutics has announced a proposed public offering of its common stock aimed at raising funds for working capital and clinical development. The company is focused on enhancing regulatory T cell function to treat neurodegenerative disorders. The offering is contingent on market conditions and will include an option for underwriters to purchase additional shares. A formal prospectus will be filed with the SEC, detailing the terms of the offering.
Read more →COYACoya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
Coya Therapeutics has completed patient enrollment for a study investigating the combination of low-dose IL-2 and CTLA4-Ig in treating Frontotemporal Dementia. The study, which has enrolled a total of 9 patients, is progressing without safety concerns. Results are expected in Q4 2025, following data analysis after the study's completion.
Read more →COYACoya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
Coya Therapeutics has launched the ALSTARS Trial, a Phase 2 clinical study to evaluate the efficacy and safety of COYA 302 in patients with Amyotrophic Lateral Sclerosis (ALS). The trial will enroll 120 participants across 25 centers in the U.S. and Canada, featuring a 24-week treatment period followed by a 24-week extension. COYA 302 aims to enhance regulatory T cell function, potentially offering a new therapeutic approach for ALS.
Read more →COYACoya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of ...
Coya Therapeutics announced promising results for COYA 303, a combination therapy of LD-IL-2 and GLP-1RA, in preclinical studies. The investigational treatment showed significant anti-inflammatory effects and improved Treg function in a mouse model of neuroinflammation. The findings support further exploration of COYA 303 for conditions like Alzheimer's Disease, where inflammation plays a key role.
Read more →COYACoya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
Coya Therapeutics' COYA 302 trial has been accepted as a NEALS-affiliated study, which will help accelerate the development of new ALS treatments. The Phase 2 clinical trial is set to begin in Q4 2025, following FDA acceptance of the IND. The trial will be presented at a NEALS Educational Webinar on September 29, 2025.
Read more →COYACoya Therapeutics to Participate at Upcoming September Investor Conferences Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
Coya Therapeutics, Inc. will participate in two investor conferences in September 2025. The H.C. Wainwright 27th Annual Global Investment Conference is scheduled for September 10, followed by the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11. Coya's management will also hold one-on-one meetings with interested investors.
Read more →COYACoya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
Coya Therapeutics reported its second-quarter financial results and provided a corporate update, highlighting the submission of additional nonclinical data to the FDA for COYA 302. The company published significant research linking inflammation to Parkinson's Disease and announced a new U.S. patent for an IL-2 formulation. However, financial results showed a net loss increase and a substantial drop in collaboration revenues.
Read more →COYACoya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update HOUSTON, TX
Coya Therapeutics, Inc. reported its second quarter financial results for 2025, highlighting key corporate developments and upcoming milestones. The company submitted additional data to the FDA for the Phase 2 trial of COYA 302 in ALS and announced a new patent for a stable IL-2 formulation. However, Coya faced a net loss of $6.1 million and a significant drop in collaboration revenues compared to the previous year. The company remains focused on advancing its clinical programs amid financial pressures.
Read more →COYA▼ -6.2%on this news
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update Houston, TX
Coya Therapeutics has reported its first quarter financial results and provided updates on its clinical programs. The company announced positive interim results from a study using low-dose IL-2 and CTLA4-Ig for treating Frontotemporal Dementia. Financially, Coya's net loss increased to $7.3 million compared to the previous year, reflecting higher research and development expenses. The company is also set to file applications for clinical trials in ALS and FTD by the end of Q2 2025 and 2025 respectively.
Read more →COYA▼ -5.8%on this news
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results Houston, TX
Coya Therapeutics has provided a corporate update alongside its fiscal 2024 financial results, reporting notable progress in its clinical trials for Alzheimer's and Frontotemporal Dementia. The company has successfully enrolled patients in their studies and announced positive preliminary outcomes from trials involving low-dose interleukin-2. Financially, Coya raised $10 million in a private placement and received a strategic investment of $5 million from the Alzheimer's Drug Discovery Foundation. However, the company reported an increased net loss compared to the previous year, indicating rising operational costs.
Read more →COYA▲ +7.7%on this news
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results Houston, TX
Coya Therapeutics has provided an update detailing positive developments in its research and financials for Q3 2024, including encouraging results from an LD IL-2 study for Alzheimer's disease presented at a major conference. The company is advancing its pipeline targeting neurodegenerative diseases, including ALS, while aligning with the FDA on necessary data to support upcoming trials. Additionally, Coya's CEO highlighted the strategic opportunities anticipated for 2025, as the firm prepares for a busy year of clinical milestones. Despite facing a net loss and increasing expenses, Coya's recent capital raise may help facilitate its ongoing projects and partnerships.
Read more →COYA▼ -27.7%on this news
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer s Disease (AD) Presented at the Clinical Trials on Alzheimer s Disease Conference (CTAD24
Coya Therapeutics has announced positive findings from a Phase 2 clinical trial of subcutaneous low-dose interleukin-2 (LD IL-2) for Alzheimer's Disease, presented at the CTAD24 conference. The trial demonstrated that LD IL-2 is safe and well-tolerated, showing positive effects on regulatory T cells and cognitive function, particularly in the LD IL-2 administered every four weeks group. Results also indicated improvements in cerebrospinal fluid biomarkers associated with Alzheimer's pathology. The study's findings support further exploration of LD IL-2 as a potential treatment for Alzheimer's Disease.
Read more →COYA▲ +16.4%on this news
Coya Therapeutics Announces $10.0 Million Private Placement - Majority of investors in offering are existing institutional stockholders of Coya HOUSTON, TX
Coya Therapeutics announced a private placement of $10 million, primarily supported by existing institutional investors. The offering entails the sale of 1,379,314 shares at a price of $7.25 per share, with proceeds expected to facilitate general corporate purposes and ongoing clinical activities. The transaction is set to close by October 23, 2024, pending customary conditions. Coya aims to leverage the funds to advance its development of therapies targeting regulatory T cells for various diseases.
Read more →COYA▲ +9.8%on this news· ran to +21% by day 3
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1 st , 2024 Dr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1st,
Coya Therapeutics has announced the promotion of Dr. Arun Swaminathan to Chief Executive Officer, effective November 1, 2024. He will succeed Dr. Howard Berman, who will transition to Executive Chair of the Board. Dr. Swaminathan's experience in business development and operations is expected to guide the company through its next growth phase. Coya is preparing for data regarding Alzheimer's at the upcoming CTAD24 conference, while also advancing its product candidates for conditions like ALS and FTD.
Read more →COYA▼ -12.9%on this news
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results Houston, TX
Coya Therapeutics has provided a corporate update detailing its financial results for Q2 2024 and significant advancements in its pipeline focused on neurodegenerative diseases. The company announced the receipt of a $5 million strategic investment for its COYA 302 treatment targeting Frontotemporal Dementia and presented encouraging biomarker data predictive of survival in ALS patients. However, the FDA has requested additional data before the start of the Phase 2 study of COYA 302, adding complexity to its developmental timeline. Coya also recorded an increase in research and development expenses, highlighting the financial challenges ahead.
Read more →COYACoya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer s Drug Discovery Foundation (ADDF) Funds will help support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD) COYA
Coya Therapeutics has announced a strategic investment of $5 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of its drug COYA 302 for Frontotemporal Dementia (FTD). This investment aligns with ADDF's commitment to advancing combination therapies for Alzheimer's and related dementias. The combined therapeutic approach of COYA 302 addresses neuroinflammation, a key factor in neurodegenerative diseases. Coya is preparing for a planned Phase 2 trial to further evaluate COYA 302's efficacy in treating FTD.
Read more →COYA▲ +5.4%on this news
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results Houston, TX
Coya Therapeutics has announced its corporate update and unaudited financial results for Q1 2024, highlighting advancements in the development of COYA 302 for ALS and other neurodegenerative diseases such as Alzheimer's, Parkinson's, and Frontotemporal Dementia. The company held successful meetings with the FDA, which may facilitate upcoming IND filings and clinical trials. Additionally, Coya presented promising biomarker data that correlates with ALS patient outcomes. However, the financial results reveal an increased net loss and rise in research and development costs compared to the previous year.
Read more →COYACoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results Houston, TX
Coya Therapeutics reported positive corporate developments and financial results for fiscal year 2023, highlighting a successful IPO and collaboration with Dr. Reddy's for its COYA 302 candidate targeting ALS. Positive clinical outcomes were presented for both ALS and Alzheimer's studies, suggesting potential for the company’s therapeutic approaches. The company announced plans to file an IND for COYA 302 in 2024, further expanding its focus on multiple neurodegenerative diseases. Furthermore, financial backing appears robust with substantial cash reserves and new revenue streams anticipated.
Read more →COYA▼ -7.7%on this news
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc. Secretary Ross has over 55 years experience as a business leader, banker, and investor and is the former Chairman and
Coya Therapeutics, Inc. has appointed Wilbur L. Ross, the former U.S. Secretary of Commerce, to its board of directors. Ross brings over 55 years of experience in business and investment to the role, which Coya intends to leverage for strategic partnerships and drug development initiatives. He expressed excitement about contributing to Coya's mission of translating T cell biology into promising therapies for serious diseases such as ALS and Alzheimer's. This appointment is viewed as a significant step in Coya's ongoing transformation and development efforts.
Read more →COYACoya Therapeutics, Inc. and Dr. Reddy s Laboratories enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sc
Coya Therapeutics, Inc. has partnered with Dr. Reddy's Laboratories for the development and commercialization of COYA 302, an investigational therapy for amyotrophic lateral sclerosis (ALS). The agreement grants Dr. Reddy's exclusive rights in several regions while allowing Coya to retain rights in others. Coya expects to file for regulatory approval in the U.S. in the first half of 2024, backed by substantial financial support from Dr. Reddy's that includes upfront payments and potential milestone earnings. Initial clinical studies indicate positive outcomes, positioning COYA 302 as a promising candidate for ALS treatment.
Read more →COYACoya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnolog
Coya Therapeutics, Inc. reported its Q3 2023 financial results and provided several updates on its clinical trials. The company has completed enrollment for a Phase 2 study of Low Dose IL-2 in Alzheimer's patients, with topline results expected in Summer 2024. Significant advancements were made through the licensing of Exosome Engineering Technology, broadening Coya's treatment capabilities. Additionally, encouraging data related to Coya's ALS treatment were presented, affirming the company's strong pipeline and future plans.
Read more →COYAFormer CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya s Board of Directors Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer s fully integrated $20 bi
Coya Therapeutics, Inc. has appointed Dieter Weinand, the former CEO and Chairman of Bayer Pharma AG, to its Board of Directors. His extensive experience in the pharmaceutical industry is expected to guide Coya's strategic discussions and development programs. Weinand expressed his optimism about Coya's potential to make significant clinical advancements for patients with neurodegenerative diseases. This appointment is seen as a strengthening move for Coya at a crucial time.
Read more →COYACoya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results HOUSTON, TX -- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-sta
Coya Therapeutics announced strong Q2 2023 results with positive data from clinical studies of their ld IL-2 therapies for Alzheimer's Disease and Amyotrophic Lateral Sclerosis. The company highlighted significant improvements in Treg function and cognitive measures among patients, with anticipation for FDA engagement for Phase 2 trials. Coya also provided updates on their expanding patent estate and management team changes, positioning itself for future growth. Overall, Coya projects an optimistic outlook for their development pipeline and strategic initiatives.
Read more →COYACoya Therapeutics CEO Dr. Howard Berman s Letter to Stockholders HOUSTON (BUSINESS WIRE) Coya Therapeutics, Inc. (NASDAQ: COYA) ( Coya or the Company ), a clinical-stage biotechnology company developing biologics intende
Coya Therapeutics CEO Dr. Howard Berman communicated key updates to stockholders, highlighting significant clinical results from their biologic programs COYA 302 and COYA 301 in Alzheimer's Disease and ALS. The company plans to present biomarker data supporting these findings in the second half of 2023, with a Phase 2 trial of COYA 302 expected to begin following FDA approval early next year. While optimistic, the CEO noted that it may be premature to continue studies on COYA 301 for frontotemporal dementia. Coya is also exploring business development opportunities to enhance therapeutic combinations.
Read more →COYA▲ +10%on this news
Coya Therapeutics COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer s Disease The open-label study evaluated the safety and tolerability, biological activity,
Coya Therapeutics has announced positive results from an open-label study of COYA 301, a treatment aimed at improving Treg function in patients with Alzheimer's disease. The study showed a statistically significant improvement in cognitive function without a decline in scores on other cognitive measures. The treatment was well tolerated, with mild side effects reported. Coya plans to further analyze the data to determine subsequent steps in its development of immunotherapies for neurodegenerative diseases.
Read more →COYACoya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a
Coya Therapeutics, Inc. reported its Q1 2023 financial results, highlighting positive outcomes from its clinical studies, including promising data for COYA 302 in ALS. The company plans to present additional findings on COYA 301 for Alzheimer's Disease at upcoming conferences. Coya has also strengthened its business development team and expanded licensing agreements with major partners. Despite these advancements, the company recorded a net loss of $2.7 million, reflecting a significant increase in operational costs compared to the previous year.
Read more →COYA▲ +6.4%on this news
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results HOUSTON —Coya Therapeutics, Inc. ( Nasdaq: COYA) (“Coya” or the “Company”), a clinical-s
Coya Therapeutics, Inc. announced its unaudited financial results for FY 2022, reporting a net loss increase attributed to elevated R&D and administrative expenses. The company highlighted positive clinical findings for its COYA 302 candidate in ALS and successfully raised $14.5 million through its IPO. Coya is advancing multiple pipeline programs targeting neurodegenerative diseases, with ongoing collaborations that support its strategic initiatives. Moving forward, Coya anticipates filing for key clinical studies and continuing to develop its Treg-focused therapies.
Read more →COYADisclosures Mitsubishi Tanabe Pharma - Member of Clinical Advisory Board; Eledon Pharmaceuticals - Consultant; Implicit Bioscience - Consultant; Coya Therapeutics - Chair of Scientific Advisory Board Disclosures The Hous
Coya Therapeutics has entered an exclusive licensing agreement with Houston Methodist Hospital for its investigational product COYA 302 targeted for ALS treatment. The product aims to address neuroinflammation associated with the disease. Clinical results suggest that the combination therapy of IL-2 and CTLA4-Ig increased Treg function and was well tolerated by patients over a 48-week trial. Importantly, no serious adverse events were recorded during the study, indicating a favorable safety profile for the treatment.
Read more →COYACoya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been published in peer-reviewed journal Neurology, Neuroimmunology & Neuroinflammation C
Read more →COYACoya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases
Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional moieties and demonstrate potent immunomodulatory function on pro-inflammatory mye
Read more →COYACoya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
Proprietary technology generates Exosome Polymer Hybrids (EPHs) which allow for efficient and versatile method of customizing cargoes of Treg-derived exosomes using oligonucleotide tethers Delivering EPHs to sites of inflammation or epitopes that drive specific diseases, while d
Read more →COYACoya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the immune system back to its functional state Preclinical data exhibit positive effects of Tre
Read more →COYACoya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS
HOUSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and
Read more →COYACoya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
HOUSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and a
Read more →COYACoya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chief Technical Officer
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya”), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disea
Read more →COYACoya Therapeutics Appoints Gene Mack as Chief Financial Officer
HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disease
Read more →COYACoya Therapeutics to Participate at the LifeSci Partners Summer Symposium
HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disease
Read more →COYACoya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologous Treg Cell Therapy, for the Treatment of ALS
Completed Phase 2a trial with full data release by end of summer 2021 HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-de
Read more →COYACoya Therapeutics to Host Key Opinion Leader Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis
-Featuring Stanley H. Appel, M.D., internationally renowned researcher and neurologist- -Webinar to be held Friday, June 11, 2021 at 11:30 a.m. ET- HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing fir
Read more →COYACoya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors
HOUSTON, May 25, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseas
Read more →COYACoya Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit
HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseas
Read more →COYACoya Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
HOUSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune dise
Read more →COYACoya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors
HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune dis
Read more →COYACoya Therapeutics™ Announces Formation of Scientific Advisory Board
HOUSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics for neurodegenerative and autoimmune dis
Read more →COYACoya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases
-Seminal discoveries in regulatory T-cell (Treg) biology; Novel cryopreservation and manufacturing innovations based on the research of Stanley H. Appel, M.D., internationally renowned researcher and neurologist- HOUSTON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc.
Read more →Competitive Position
How COYA ranks across every disease it competes inCompetitive Position is a premium feature
See how COYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial